It was already published by BMRN they were doing this so they could meet with EU regulators first on a patient that already had elevated ALT levels. They should have publized it more, because all they did was update the trial site based on what they said they were going to do several weeks ago. It's a non-event that has turned in an event based on poor PR. I bought a 1000 more shares on the dip. Take advantage while the BS sale is ongoing.
Interesting , it's best he is on your side not against. Must be an article coming out from The Street, or Jim Cramer will mention as a spec play. AFs rule on investing in small bios has an over 90% accuracy rate for spotty failures. So he must think CTIX is a winner.
Than Ortezla, no doubt when you factor in the safety profile. The higher dosages in the next trial will completely blow away the competition. From the looks of the PH-II Trial higher dosing results. Then there is K. Results should be soon.
Odd that its rumored to be MRK. I could see $132 as the starting prices probably 20% where it will end up. Since the rumor is MRK, I almost believe it.
It's all about milestones. Throw out the technical s for now. P, B-OM, B, K can all re-price this stock. Court dismissal of the Rosen Lawsuit too.
revenue growth, EPS beats and they are actually hiring. Look for the rotation back into Healthcare. Now is the time to buy.
Do they cover the same space? I thought Prurisol is for mild to moderate not moderate to severe?
to sleep on this one and get a 100% no brainer return.
Looks like the market is providing that opportunity again. The headline on Rev miss is a joke. Why not say Rev missed by .003...lol. Strong $ which has gotten weaker since.